Introduction
============

Renal cell carcinoma (RCC) is one of the most common genitourinary cancers worldwide.[@b1-ott-9-6399] An estimated 61,560 new cases of RCC were expected in the US in 2015.[@b2-ott-9-6399] Chromophobe renal cell carcinoma (chRCC) is a relatively rare subtype of RCC, accounting for approximately 5% of all patients.[@b3-ott-9-6399] Compared to other RCC subtypes, chRCC has significantly higher cancer-specific survival probabilities. Prognosis for patients with chRCC has improved in past decades due to technological advances in early detection and intervention.[@b4-ott-9-6399] Even so, the clinical behavior and long-term outcomes of chRCC are still highly variable. Hence, identifying novel molecular biomarkers and studying the detailed molecular mechanism of chRCC are necessary.

Noncoding RNAs with length greater than 200 nucleotides are cataloged as long noncoding RNAs (lncRNAs).[@b5-ott-9-6399] LncRNAs are usually short of meaningful open reading frames (ORFs) and not translated into proteins, but they can regulate the gene expression in the form of RNA in many aspects.[@b6-ott-9-6399],[@b7-ott-9-6399] Competitive endogenous RNA (ceRNA) hypothesis was proposed by Salmena et al in 2011. They pointed out that some messenger RNAs and noncoding RNAs such as pseudogene, lncRNAs, and circular RNAs can regulate the target genes by competitive binding to the same microRNA (miRNA)-binding sites through miRNA response elements (MREs), so the inhibition of target genes by miRNA can be released or lessened.[@b8-ott-9-6399] This is to say that lncRNA--miRNA--mRNA may form a large and subtle regulatory RNA network in tumors. To date, various lncRNA and miRNA interactions with significant functions have been identified in many cancers.[@b9-ott-9-6399]--[@b11-ott-9-6399] In RCC, lncRNA MALAT1 was found to function as a competing endogenous RNA to regulate epithelial--mesenchymal transition-related proteins by sponging miR-200s and miR-205, and HOTAIR was proved to promote the proliferation and invasion of renal clear cell adenocarcinoma cells 786-O by interacting with miR-141.[@b12-ott-9-6399]--[@b15-ott-9-6399] However, more functions of lncRNA in chRCC remain to be elucidated.

In this study, we analyzed the expression data of lncRNA, miRNA, and protein-coding RNA and the corresponding clinical information of 59 chRCC patients selected from The Cancer Genome Atlas (TCGA) database to explore the differential expression profiles of lncRNAs in different clinical statuses and to identify tumor-specific lncRNAs' competing endogenous RNA potential in the tumor.

Methods
=======

Data collection
---------------

Fifty-nine chRCC patients selected from the TCGA database were enrolled in our study. The inclusion criteria were set as follows: 1) the tumor histological type was chRCC; 2) the patient did not have a history of other malignancies; 3) the patient had not received neoadjuvant therapy; and 4) the clinical information was complete. Among these 59 patients (Cohort T), 23 patients provided the adjacent nontumor tissues (Cohort M). Their corresponding RNA expression data (level 3) were downloaded from TCGA data portal (<http://cancergenome.nih.gov>, up to Jan 20, 2016). These gene expression profiles were produced by using Illumina HiSeq 2000 sequencer platforms (Illumina Inc., San Diego, CA, USA). The raw expression data of lncRNAs and mRNAs which were generated from RNA sequencing raw reads by RNASeqV2 postprocessing pipelines were normalized as RNA-Seq by Expectation-Maximization. The raw expression data of miRNAs were standardized as reads per million by the TCGA project. Patient data were collected and processed following the data access policies approved by the Ethics Committee of The Cancer Genome Atlas Program. The authors downloaded all the data from the TCGA database and performed this study in line with the TCGA publication guidelines (<http://cancergenome.nih.gov/publications/publicationguidelines>). All patients enrolled in the program were well informed. Therefore, no further ethical approval was required for this study. We analyzed these expression profiles with BRB-Array tools (version 4.4.0) developed by Dr Richard Simon and the BRB-Array Tools Development Team.[@b16-ott-9-6399]

Construction of lncRNA-associated ceRNA network
-----------------------------------------------

LncRNA-associated ceRNA network was constructed based on the "ceRNA hypothesis" that lncRNAs can regulate the expression of mRNAs which contain common MREs by combining the miRNAs competitively. We identified differentially expressed lncRNAs and miRNAs (fold change ≥5.0, *P*\<0.001) in the tumor. Predicted human miRNA--lncRNA interactions were collected from starBase v2.0[@b17-ott-9-6399] and miRcode.[@b18-ott-9-6399] Experimentally validated miRNA--target mRNA interactions were retrieved from the miRTarBase.[@b19-ott-9-6399] Differentially expressed miRNAs were set as hub nodes. The lncRNAs and mRNAs were connected with these hub nodes according to their interactions. Maximal information coefficient (MIC) algorithm was used to identify the robustness of pair-wise relationships of miRNA--lncRNA and miRNA--mRNA (MIC \>0.15, MIC-ρ2 \>0.15).[@b20-ott-9-6399] Cytoscape v3.0[@b21-ott-9-6399] was applied to construct and visualize the network graph.

Functional enrichment analysis
------------------------------

Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of the coding RNAs involved in the ceRNA network was conducted using Database for Annotation, Visualization, and Integrated Discovery.[@b22-ott-9-6399] We did the analysis with default parameters. The whole human genome was set as background; functional categories with *P*-value \<0.05 were regarded as statistically significant.

Statistical analysis
--------------------

Clinical category variables were presented as counts and percentages. The chi-square test was applied to analyze differences of distribution between Cohort M and Cohort T. RNA expression data were presented as mean ± standard deviation. Paired sample *t*-test was used to examine differences in lncRNA and miRNA expression between cancerous and matched adjacent tissues (significant *P*-value was set as 0.001). Unpaired *t*-test was conducted to find out the difference in lncRNA expression levels between different clinicopathological groups (significant *P*-value was set as 0.01). Unsupervised hierarchical cluster analysis was used to generate tree clusters for the separation of different classes with lncRNA expression profiles. Univariate Cox proportional hazards regression was applied to identify the lncRNAs associated with overall survival; Kaplan--Meier survival analyses and log-rank test were performed to study the relations of lncRNA expression states (cutoff point: median value) and survival time (significant *P*-value was set as 0.05). All statistical analyses were performed by the SPSS 19 (IBM Corporation, Armonk, NY, USA) and BRB-Array Tools 4.0.

Results
=======

Patient characteristics
-----------------------

A total of 59 chRCC patients were enrolled in our study. Among them (Cohort T), 23 patients provided adjacent tissues (Cohort M). Their demographic characteristics and clinical information are summarized in [Table 1](#t1-ott-9-6399){ref-type="table"}.

Differential expression analysis of lncRNAs
-------------------------------------------

We identified 605 lncRNAs from the TCGA level 3 RNASeqV2 data according to the classification of HUGO Gene Nomenclature Committee (HGNC) (<http://www.genenames.org>). A total of 143 lncRNAs were found to be expressed differentially between the cancer and the paired adjacent tissues (fold change ≥1.5, *P*\<0.001) ([Table S1](https://www.dovepress.com/get_supplementary_file.php?f=116392.pdf)). Unsupervised hierarchical clustering could clearly discriminate cancer and normal class with these differentially expressed lncRNAs ([Figures S1](https://www.dovepress.com/get_supplementary_file.php?f=116392.pdf) and [S2](https://www.dovepress.com/get_supplementary_file.php?f=116392.pdf)). In consideration of the fold change, 43 of them had an absolute fold change ≥5.0, and they were selected to build the ceRNA network ([Table 2](#t2-ott-9-6399){ref-type="table"}). Furthermore, among these 143 differentially expressed lncRNAs, 12 cancer-specific lncRNAs were also identified to be differentially expressed in different clinical features (fold change ≥1.5, *P*\<0.01) with 3 for gender, 1 for age, 5 for tumor status, and 3 for American Joint Committee on Cancer stage and tumor size ([Table 3](#t3-ott-9-6399){ref-type="table"}). Because the number of patients with metastasis status M1 and lymph node status N1+N2 was too small, class comparison analyses were not conducted for them.

LncRNAs in relation to patient prognosis
----------------------------------------

Among differentially expressed lncRNAs, 7 lncRNAs (COL18A1-AS, BRE-AS1, SNHG7, TMEM51-AS1, C21orf62-AS1, LINC00336, and LINC00882) were identified to be associated with the overall survival of chRCC by univariate Cox regression analysis. Kaplan--Meier survival curves indicated that COL18A1-AS1 (*P*=0.009), BRE-AS1 (*P*=0.011), SNHG7 (*P*=0.014), TMEM51-AS1 (*P*=0.024), C21orf62-AS1 (*P*=0.027), and LINC00336 (*P*=0.037) were positively correlated with overall survival, while the remaining LINC00882 (*P*=0.047) was negatively associated with overall survival ([Figure 1](#f1-ott-9-6399){ref-type="fig"}).

LncRNA-associated ceRNA network
-------------------------------

Thirty-one miRNAs identified to be expressed differentially between the cancer and adjacent tissues with absolute fold change higher than 5 (*P*\<0.001) ([Table S2](https://www.dovepress.com/get_supplementary_file.php?f=116392.pdf)) were selected to construct the ceRNA network. In a ceRNA network, miRNAs interact with lncRNAs through MREs, and we used miRcode and starBase v2.0 to find the potential MREs of these miRNAs in tumor-specific lncRNAs, as described in [Table 2](#t2-ott-9-6399){ref-type="table"}. The result demonstrated that 18 of 31 cancer-specific miRNAs might interact with 16 of 43 cancer-specific lncRNAs ([Table 4](#t4-ott-9-6399){ref-type="table"}). Subsequently, 167 experimentally validated target genes of miRNAs described in [Table 4](#t4-ott-9-6399){ref-type="table"} were identified by using miRTarBase ([Table 5](#t5-ott-9-6399){ref-type="table"}), and all these miRNA--mRNA interactions were validated by reporter assay, Western blot, and qPCR. Then, an lncRNA--miRNA--mRNA network was established based on the above-mentioned data ([Tables 4](#t4-ott-9-6399){ref-type="table"} and [5](#t5-ott-9-6399){ref-type="table"}). The MIC algorithm was applied to test pair-wise correlations based on their expression levels. To enhance the robustness of the ceRNA network, only those pair-wise interactions with MIC \>0.15 and MIC-ρ2 \>0.15 were included in the ceRNA network ([Figure 2](#f2-ott-9-6399){ref-type="fig"}).

KEGG pathway enrichment analysis
--------------------------------

To explore the biological functions of these protein-coding RNAs involved in the ceRNA network, KEGG pathway enrichment analysis was conducted using Database for Annotation, Visualization, and Integrated Discovery. As summarized in [Table 6](#t6-ott-9-6399){ref-type="table"}, 12 cancer-related pathways were enriched, including those for prostate cancer, melanoma, pancreatic cancer, chronic myeloid leukemia, colorectal cancer, bladder cancer, glioma, RCC, small cell lung cancer, endometrial cancer, and acute myeloid leukemia, and 6 non-cancer-related pathways were enriched, including those for focal adhesion, adherens junction, cell cycle, neurotrophin signaling pathway, ErbB signaling pathway, and p53 signaling pathway.

Discussion
==========

RCC has various histological subtypes, of which clear-cell RCC (about 70%), papillary RCC (about 10%--15%), and chRCC (about 5%) are the most prevalent.[@b3-ott-9-6399] These subtypes have diverse genetic and clinical features, and the identification of molecular mechanisms behind their oncogenesis and progression comprises an important area of cancer research.[@b4-ott-9-6399],[@b23-ott-9-6399] In the present study, we focused on exploring the prognostic roles and the competing endogenous RNA potential of lncRNAs in chRCC. By analyzing the clinical information and large-scale sequencing data pertaining to a chRCC patient cohort, we identified tumor-specific lncRNAs in chRCC and investigated their distribution in different clinical features and prognoses. Besides, we constructed an lncRNA-related ceRNA network of chRCC consisting of lncRNAs, miRNAs, and protein-coding RNAs.

As a highly heterogeneous group of noncoding RNAs, lncRNAs can regulate the gene expression by means of diverse mechanisms and are involved in various biological processes.[@b5-ott-9-6399],[@b24-ott-9-6399] Mounting evidences suggest lncRNAs have key roles in regulation of tumor development and progression.[@b10-ott-9-6399],[@b25-ott-9-6399] These aberrantly expressed lncRNAs could be tracked in the migration, apoptosis, proliferation, and drug resistance patterns of tumor cells, which implies that lncRNAs could serve as potential therapeutic targets and biomarkers.[@b26-ott-9-6399]--[@b29-ott-9-6399] Numerous studies have documented that lncRNAs could affect the expression of cancer-related proteins by interacting with miRNAs, somewhat validating the ceRNA hypothesis.[@b14-ott-9-6399],[@b15-ott-9-6399] In order to gain more insight about their effects in tumors, lncRNA profiling has become a major method to study the widespread dysregulated lncRNAs, and their coexpression networks with mRNAs and miRNAs have been constructed in various tumors.[@b30-ott-9-6399]--[@b32-ott-9-6399] However, such lncRNAs-related ceRNA networks in RCC are still poorly explored.

Hence, we conducted the present study with the aim to identify lncRNA biomarkers of prognosis and construct an lncRNA--miRNA--mRNA coexpression network in chRCC. By analyzing the lncRNA expression profiles of 59 primary chRCC patients, we identified 142 differentially expressed lncRNAs between cancer and adjacent tissues, 43 of which had a more than a fivefold change in expression levels. In those upregulated lncRNAs, CDKN2B-AS1 has previously been reported to be able to promote cell proliferation. Furthermore, its high expression has been linked to poor prognosis in prostate and gastric cancer.[@b33-ott-9-6399],[@b34-ott-9-6399] The expression level of SLC26A4-AS1 was found to be significantly associated with overall higher survival of gastric cancer patients, but the mechanism was not elaborated.[@b35-ott-9-6399] In those downregulated lncRNAs, CASC2 was found to be aberrantly expressed in glioma and non-small-cell lung cancer. Increase in CASC2 expression could inhibit cell proliferation of the 2 tumors, and CASC2 was proved to be an independent predictor of overall survival for non-small-cell lung cancer patients.[@b36-ott-9-6399] In addition, 12 tumor-specific lncRNAs were found to be abnormally expressed in different clinical features. Dysregulated lncRNAs identified by tumor stage or size are identical because patients' distributions in their different groups are common. As the number of patients with metastasis status M1 and lymph node status N1 + N2 was too small, class comparison analyses were not conducted. In consideration of the relationship between cancer-specific lncRNAs and prognosis, we identified 7 lncRNAs that were associated with chRCC overall survival, and they may serve as prognosis prediction tools or candidate drug targets for chRCC management. Among the 6 protective lncRNAs, SNHG7 was reported to be involved in the cellular response to radiation-induced oxidative stress.[@b37-ott-9-6399] The functions of the other 5 protective and 1 risky lncRNA are still unknown.

For further analyzing the interactions between lncRNA, miRNA, and mRNA in chRCCs, we constructed a ceRNA network by bioinformational methods. This ceRNA network contained 16 tumor-specific lncRNAs, 18 tumor-specific miRNAs, and 168 protein-coding RNAs. To improve the prediction accuracy of the coexpression network, pair-wise relationships of lncRNA--miRNA--mRNA were filtered based on their expression levels by the MIC algorithm which could detect novel associations in complex datasets. Through KEGG analysis, we found that those ceRNA network-involved genes were mainly enriched in cancer-related pathways, further indicating that lncRNAs may play a vital role in tumor molecular regulatory networks. The ceRNA network we constructed reveals an unknown ceRNA regulatory network in chRCC and gives some new perspectives of lncRNAs' functions in gene regulation. However, some issues should be acknowledged in interpreting this ceRNA network. The network was constructed in silico and could serve as a reference for further research. For validation of the lncRNA/miRNA/mRNA pathway, additional biological experiments need to be conducted.

Conclusion
==========

By analyzing an independent chRCC patient cohort extracted from the TCGA database, we screened differentially expressed lncRNAs under different clinical features and constructed an lncRNA-related ceRNA network. Our study suggests that some lncRNAs are associated with chRCC progression and prognosis, and they may function as ceRNAs in a complex ceRNA network.
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###### 

Clinical characteristics of patients with chromophobe renal cell carcinoma

  Category                   Cohort M    Cohort T    *P*-value
  -------------------------- ----------- ----------- -----------
  Age, mean ± SD             52.6±13.3   51.0±14.2   0.647
  Gender, n (%)                                      0.623
   Female                    12 (52.2)   26 (44.1)   
   Male                      11 (47.8)   33 (55.9)   
  AJCC stages, n (%)                                 0.594
   Stage I                   9 (39.2)    17 (28.9)   
   Stage II                  8 (34.8)    23 (39.0)   
   Stage III                 3 (13.0)    14 (23.7)   
   Stage IV                  3 (13.0)    5 (8.4)     
  Tumor size, n (%)                                  0.790
   T1                        9 (39.1)    17 (28.8)   
   T2                        8 (34.8)    23 (39.0)   
   T3                        5 (21.7)    14 (23.7)   
   T4                        1 (4.4)     5 (8.5)     
  Lymph node, n (%)                                  0.382
   N0                        11 (47.8)   38 (64.4)   
   N1+N2                     2 (8.7)     4 (6.8)     
   NX                        10 (43.5)   17 (28.8)   
  Metastasis status, n (%)                           0.947
   M0                        18 (78.3)   48 (81.4)   
   M1                        1 (4.4)     2 (3.4)     
   MX                        4 (17.3)    9 (15.2)    
  Tumor status, n (%)                                0.783
   Tumor free                19 (82.6)   50 (84.7)   
   With tumor                3 (13.0)    8 (13.6)    
   NA                        1 (4.4)     1 (1.7)     

**Abbreviations:** AJCC, American Joint Committee on Cancer; NA, not applicable; SD, standard deviation.

###### 

Forty-three cancer specific lncRNAs in ceRNA network construction

  LncRNA        Entrez ID   Chromosome   Expression change (T vs N)
  ------------- ----------- ------------ ----------------------------
  LINC00588     26138       Chr8         Upregulation
  SLC26A4-AS1   286002      Chr7         Upregulation
  BAALC-AS2     157556      Chr8         Upregulation
  LINC00265     349114      Chr7         Upregulation
  UCKL1-AS1     100113386   Chr20        Upregulation
  LINC00239     145200      Chr14        Upregulation
  PART1         25859       Chr5         Upregulation
  PACRG-AS1     285796      Chr6         Upregulation
  KRTAP5-AS1    338651      Chr11        Upregulation
  CDKN2B-AS1    100048912   Chr9         Upregulation
  LINC00889     158696      ChrX         Upregulation
  LINC00669     647946      Chr18        Upregulation
  LINC00930     100144604   Chr15        Upregulation
  LINC00598     646982      Chr13        Upregulation
  NR2F1-AS1     441094      Chr5         Downregulation
  LINC00882     100302640   Chr3         Downregulation
  LINC00242     401288      Chr6         Downregulation
  LINC01554     202299      Chr5         Downregulation
  CASC2         255082      Chr10        Downregulation
  LINC00312     29931       Chr3         Downregulation
  TINCR         257000      Chr19        Downregulation
  LINC00092     100188953   Chr9         Downregulation
  HCG4          54435       Chr6         Downregulation
  HNF1A-AS1     283460      Chr12        Downregulation
  LOC145837     145837      Chr15        Downregulation
  MEG3          55384       Chr14        Downregulation
  LINC00839     84856       Chr10        Downregulation
  LOC285768     285768      Chr6         Downregulation
  ADORA2A-AS1   646023      Chr22        Downregulation
  GATA3-AS1     399717      Chr10        Downregulation
  LINC00924     145820      Chr15        Downregulation
  BRE-AS1       100302650   Chr2         Downregulation
  UCA1          652995      Chr19        Downregulation
  EGOT          100126791   Chr3         Downregulation
  LINC00908     284276      Chr18        Downregulation
  LINC00671     388387      Chr17        Downregulation
  LINC00271     100131814   Chr6         Downregulation
  COL18A1-AS1   378832      Chr21        Downregulation
  LINC01550     388011      Chr14        Downregulation
  WT1-AS        51352       Chr11        Downregulation
  LINC01139     339535      Chr1         Downregulation
  LINC00473     90632       Chr6         Downregulation
  LHFPL3-AS2    723809      Chr7         Downregulation

**Notes:** The names, Entrez IDs and chromosomal locations of theses lncRNAs were obtained from the Entrez Gene database <http://www.ncbi.nlm.nih.gov/gene>.[@b38-ott-9-6399]

**Abbreviations:** ceRNA, competing endogenous RNA; lncRNA, long noncoding RNA; N, normal; T, tumor.

###### 

LncRNAs associated with the progression of chromophobe renal cell carcinoma

  Comparisons                               Downregulated                  Upregulated
  ----------------------------------------- ------------------------------ -----------------------
  Gender (female vs male)                   CHKB-AS1, LOC285768            XIST
  Age at diagnosis (≥51 vs \<51)                                           LINC01119
  AJCC stage (III+IV vs I+II)               TMEM51-AS1                     LINC00242, CHKB-AS1
  AJCC T (T3+T4 vs T1+T2)                   TMEM51-AS1                     LINC00242, CHKB-AS1
  Tumor status (with tumor vs tumor free)   PSMD5-AS1, ADORA2A-AS1, INE2   CDKN2B-AS1, LINC00669

**Abbreviations:** AJCC, American Joint Committee on Cancer; lncRNA, long noncoding RNA.

###### 

Putative miRNAs that may target cancer-specific lncRNAs by MREs

  lncRNA        miRNAs
  ------------- ---------------------------------------------------------------------------------------------------------------------------------------
  LINC00473     hsa-mir-199a-1/2, hsa-mir-199b
  WT1-AS        hsa-mir-199a-1/2, hsa-mir-199b, hsa-mir-221, hsa-mir-9-1, hsa-mir-96
  COL18A1-AS1   hsa-mir-187, hsa-mir-196a-1
  LINC00271     hsa-mir-192
  EGOT          hsa-mir-183
  UCA1          hsa-mir-182, hsa-mir-190, hsa-mir-455, hsa-mir-96
  LINC00839     hsa-mir-130a
  MEG3          hsa-mir-182, hsa-mir-192, hsa-mir-199a-1/2, hsa-mir-199b, hsa-mir-204, hsa-mir-217, hsa-mir-221, hsa-mir-455, hsa-mir-9-1, hsa-mir-96
  HNF1A-AS1     hsa-mir-183, hsa-mir-194-1/2, hsa-mir-199a-1/2, hsa-mir-199b, hsa-mir-217, hsa-mir-455, hsa-mir-9-1
  HCG4          hsa-mir-217, hsa-mir-96
  LINC00312     hsa-mir-190, hsa-mir-192, hsa-mir-9-1
  CASC2         hsa-mir-130a, hsa-mir-192, hsa-mir-194-1/2
  LINC00242     hsa-mir-204, hsa-mir-217, hsa-mir-221, hsa-mir-222
  PART1         hsa-mir-9-1
  LINC00265     hsa-mir-182, hsa-mir-217
  SLC26A4-AS1   hsa-mir-130a

**Abbreviations:** lncRNA, long noncoding RNA; miRNA, microRNA; MREs, microRNA response elements.

###### 

Experimentally validated miRNA targets

  miRNA              mRNAs targeted by miRNA
  ------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  hsa-mir-130a       HOXA5, ATXN1, MEOX2, PPARG, GJA1, TNF
  hsa-mir-182        FOXO1, CDKN1A, MITF, RECK, FLOT1, PTEN, GSK3B, ANUBL1, CYLD, BCL2, CCND2, PDCD4, SATB2, CHL1, CADM1, TP53INP1, TCEAL7, ULBP2
  hsa-mir-183        FOXO1, EZR, PDCD4, AKAP12, GSK3B, SMAD4, ZFPM1, DKK3, BMI1, ZEB1, SNAI2, PPP2CB, PPP2R4
  hsa-mir-187        TNF, CD276
  hsa-mir-190        IGF1, PHLPP1, MARK2, KCNQ5
  hsa-mir-192        ALCAM, CDC7, CUL5, ERCC3, LMNB2, MAD2L1, ERCC4, RB1, WNK1, DICER1, CAV1
  hsa-mir-194-1/2    IGF1R, CDH2, RAC1, HBEGF, PTPN12, PTPN13, ITGA9, SOCS2, DNMT3A, SOX5, BMI1, RBX1, BMP1
  hsa-mir-199a-1/2   MET, MTOR, CAV1, GSK3B, FZD4, WNT2, JAG1, CD44, IKBKB, KL, CDH1, HIF1A, SMARCA2, MAPK1, DDR1, MAP3K11, FUT4, CAV2, ERBB2, SIRT1, PTGS2, HSPA5, ATF6, ERN1, HGF, WNK1, NFKB1, ACVR1B
  hsa-mir-199b       HES1, SET, PODXL, JAG1, DDR1, ERBB2, SETD2
  hsa-mir-204        BCL2, THRB, BIRC2, EZR, M6PR, RAB22A, RAB40B, SERP1, TCF12, SOX4, CDC42, RUNX2, EFNB2, SIRT1, NTRK2, USP47, ANKRD13A, TMPRSS3, CDH1, VIM, BDNF, HMX1
  hsa-mir-217        SIRT1, ROBO1, EZH2, DACH1, FOXO3, GPC5
  hsa-mir-221        CDKN1B, DDIT4, KIT, CDKN1C, BBC3, BNIP3L, FOS, BNIP3, MBD2, BMF, FOXO3, TMED7, ESR1, TICAM1, PTEN, TRPS1, WEE1, HECTD2, ASZ1, MDM2, ETS1, IMP3, DIRAS3, CERS2, ZEB2, RB1, APAF1, ANXA1, CTCF, RAB1A, RECK, SIRT1
  hsa-mir-222        CDKN1B, SOD2, MMP1, KIT, FOS, PTEN, STAT5A, FOXO3, CDKN1C, ESR1, BBC3, TRPS1, VGLL4, ETS1, TIMP3, DIRAS3, CERS2, DKK2
  hsa-mir-455        MUC1, NCSTN
  hsa-mir-9-1        RAB34, ONECUT2, FOXO1, NFKB1, NR2E1, AP3B1, CCNG1, DICER1, SIRT1, STMN1, CREB1, NF1, ELAVL1, CXCR4, FOXP1, PRTG, ACAT1, MTHFD1, BCL2L11
  hsa-mir-96         FOXO1, CDKN1A, KRAS, FOXO3, GSK3B, RECK, REV1, RAD51, ALK, ZEB1, SNAI2

**Abbreviation:** miRNA, microRNA.

###### 

KEEG pathways enriched by the protein-coding genes involved in ceRNA network with *P*\<0.001

  Pathway type                     KEGG pathways        Number of genes   *P*-value
  -------------------------------- -------------------- ----------------- --------------
  Cancer-related pathways          Pathways in cancer   37                1.25571E--19
  Prostate cancer                  17                   3.53254E--12      
  Melanoma                         12                   5.47354E--08      
  Pancreatic cancer                11                   6.62018E--07      
  Chronic myeloidleukemia          11                   9.7726E--07       
  Colorectal cancer                11                   2.83419E--06      
  Bladder cancer                   8                    1.00607E--05      
  Glioma                           9                    1.83661E--05      
  Renal cell carcinoma             9                    4.02163E--05      
  Small cell lung cancer           9                    0.000149891       
  Endometrial cancer               7                    0.000369377       
  Acute myeloid leukemia           7                    0.000671143       
  Noncancer-related pathways       Focal adhesion       16                3.59367E--06
  Adherens junction                10                   1.07149E--05      
  Cell cycle                       12                   1.72817E--05      
  Neurotrophin signaling pathway   11                   9.0498E--05       
  ErbB signaling pathway           9                    0.000191896       
  p53 signaling pathway            8                    0.000243417       

**Note:** The *P*-value is corrected for multiple hypothesis testing using the Benjamini--Hochberg method.

**Abbreviations:** ceRNA, competing endogenous RNA; KEGG, Kyoto Encyclopedia of Genes and Genomes.
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